Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?

Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most aggressive malignancies with a 5-year survival rate of <7%. Due to growing incidence, late diagnosis and insufficient treatment options, PDAC is predicted to soon become one of the leading causes of cancer-related death. Although...

Descripción completa

Detalles Bibliográficos
Autores principales: Hessmann, Elisabeth, Johnsen, Steven A, Siveke, Jens T, Ellenrieder, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Recent Advances in Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256386/
https://www.ncbi.nlm.nih.gov/pubmed/27811314
http://dx.doi.org/10.1136/gutjnl-2016-312539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256386/
https://www.ncbi.nlm.nih.gov/pubmed/27811314
http://dx.doi.org/10.1136/gutjnl-2016-312539

Ejemplares similares